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We show that DNA methyltransferase inhibitors
(DNMTis) upregulate immune signaling in cancer
through the viral defense pathway. In ovarian cancer
(OC), DNMTis trigger cytosolic sensing of double-
stranded RNA (dsRNA) causing a type I interferon
response and apoptosis. Knocking down dsRNA sen-
sors TLR3 and MAVS reduces this response 2-fold
and blocking interferon beta or its receptor abrogates
it. Upregulation of hypermethylated endogenous
retrovirus (ERV) genes accompanies the response
and ERV overexpression activates the response.
Basal levels of ERV and viral defense gene expression
significantly correlate in primary OC and the latter
signature separates primary samples for multiple
tumor types from The Cancer Genome Atlas into low
versus high expression groups. Inmelanoma patients
treated with an immune checkpoint therapy, high viral
defense signature expression in tumors significantly
associates with durable clinical response and DNMTi
treatment sensitizes to anti-CTLA4 therapy in a pre-
clinical melanoma model.
INTRODUCTION
DNA methyltransferase inhibitors (DNMTis) such as 5-azacyti-
dine (Aza) and 5-aza-20-deoxycytidine (Dac) are effective cancer
therapies in hematologic neoplasms (Issa, 2005; Matei et al.,
2012) and are Food and Drug Administration (FDA)-approved
for the pre-leukemic disorder myelodysplasia (MDS) (Kaminskas
et al., 2005). These cytidine analogs incorporate into DNA,
block catalytic actions of DNA methyltransferases (DNMTs),
and trigger their degradation (Stresemann et al., 2006). Preclini-974 Cell 162, 974–986, August 27, 2015 ª2015 Elsevier Inc.cally, low doses avoid early cytotoxicity and DNA damage,
allowing cells to exhibit apparent reprogramming and blunting
of tumorigenicity (Tsai et al., 2012). Mechanisms can include
reversal of abnormal promoter DNA methylation, re-expression
of silenced genes including tumor suppressors (Baylin and
Jones, 2011), and changes to cancer signaling pathways
including apoptosis, cell-cycle activity, and stem cell functions
(Tsai et al., 2012).
A long recognized activity of DNMTis described by others
(Karpf et al., 1999, 2004) and our group (Li et al., 2014; Wrangle
et al., 2013), is induction of immune responses in cancer cells. In
recent clinical trials for non-small cell lung cancer (NSCLC) (Juer-
gens et al., 2011;Wrangle et al., 2013) a small number of patients
had remarkably robust and durable responses to immune check-
point blockade therapy after first receiving Aza (Wrangle et al.,
2013). This immune therapy alone also has activity against
NSCLC (Brahmer et al., 2010, 2012; Topalian et al., 2012). A
larger trial is now ongoing to determine if Aza can indeed prime
patients for sensitization to checkpoint inhibition (Brahmer,
2015). For NSCLC and other tumor types, Aza induces interferon
signaling and concordant upregulation of surface antigens and
their assembly proteins, viral defense pathways, and transcript
and surface protein levels of PD-L1, the key checkpoint ligand
targeted in the above immunotherapy (Li et al., 2014; Wrangle
et al., 2013). Indeed, we have defined a 300-gene expression
signature we termed Aza-induced immune genes or AIM (Li
et al., 2014) for which activation is greatest for epithelial ovarian
cancer (EOC) and NSCLC (Li et al., 2014). Genome-wide expres-
sion of AIM separates primary EOC, NSCLC, and other cancers
into high and low expression groups (Li et al., 2014). We hypoth-
esize the low group may represent an ‘‘immune evasion/immune
editing’’ pattern (Drake et al., 2006; Schreiber et al., 2011) that
Aza could reverse to sensitize patients to subsequent immune
therapy (Li et al., 2014).
We now show that a major mechanism underlying the
Aza-triggered immune response is induction of a cytosolic
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Figure 1. DNMT Inhibitors Upregulate Im-
mune Genes in Ovarian Cancer Cell Lines
(A) Levels of immune genes in four EOC cell lines
and DKO colon cancer cell line (DNMT1/,
DNMT3B/) relative to its parental HCT116
line. y axis, log2 Aza/Mock fold change from
microarray data. Dotted line denotes 2-fold
change.
(B) qRT-PCR validation of immune genes in
EOC cells treated for 72 hr: Mock, 500 nM Aza,
or 500 nM- 3 mM carboplatin and rested for
7 days before assaying (day 10). IC50s were
A2780 (Aza, 848 nM; Carb, 457 nM), Hey (Aza,
4.1 mM; Carb, 12.2 mM), TykNu (Aza, 491 nM;
Carb, 986.2 nM).
(C and D) qRT-PCR validation of interferon
response genes in the A2780 (C) and TykNu (D)
EOC lines treated with no drug (Mock), 500 nM
Aza (Aza), or 100 nM Decitabine (Dac) for 3 days,
and rested for 4 (day 7) or 7 (day 10) days
before assaying. Data in (B)–(D) are represented
as mean ± SEM of three biological replicates,
y axis = fold change over mock. *p % 0.05.
See also Figure S1.double-stranded RNA (dsRNA) sensing pathway used by epithe-
lial and other cell types as a viral defense mechanism that trig-
gers a type I interferon response (Kulaeva et al., 2003; Sistigu
et al., 2014). A key contributor is induction of increased expres-
sion of multiple DNA hypermethylated endogenous retroviruses
(ERVs). In The Cancer Genome Atlas (TCGA), the viral defense
gene expression separates primary EOC and other cancers
into high and low expression and high tumor expression strongly
associates with clinical benefit in a trial of immune checkpoint
therapy for advanced melanoma. Aza sensitizes to immune
checkpoint blockade in a pre-clinical model of melanoma. We
thus define a potential approach in which an epigenetic therapy
may sensitize cancer cells to various immunotherapies.
RESULTS
DNMTis Trigger Viral Defense and Type I Interferon
Signaling
Induction of AIM in a previous study of 23 EOC cell lines (Li et al.,
2014) included, in addition to previously reported DNA hyperme-
thylated cancer testis antigens (MAGEA4, MAGEA9, NY-ESO-1)
(James et al., 2013; Karpf et al., 2004, 2009; Odunsi et al., 2014),
interferon/viral defense, antigen processing and presentation,
and host immune cell attraction genes (Figure 1A). Direct Aza
targeting of DNMTs for these changes is suggested by similar
findings in DKO colon cancer cells genetically disrupted for
two major DNMTs (DNMT1/, DNMT3B /) versus parental,
wild-type HCT116 cells (Figure 1A). The induced responses
may not be a general stress phenomenon as they did not occur
with carboplatin, a cytotoxic agent commonly used in EOC treat-
ment (Figure 1B). Aza and Dac incorporate into DNA, inhibiting
three DNA methyltransferases, but Aza also incorporates into
RNA, inhibiting the RNA methyltransferase DNMT2 (Schaefer
et al., 2009). Aza thus can demethylate RNA, and unmethylatedRNA may activate TLR3 and the interferon response (Kariko´
et al., 2005). However, Dac and Aza both mimicked the DKO
cell line results (Figures 1A, 1C, 1D, S1A, and S1B) strongly sug-
gesting that the drugs directly target DNA methylation to trigger
the interferon response.
Aza and Dac similarly triggered an interferon response that in-
cludes interferon beta (IFNb1) and a panel of interferon-stimu-
lated genes (ISGs) (IFI16, IFI27, IFI44, IFI44L, MX1, and OASL)
(Figures 1C, 1D, S1A, and S1B). Each ISG functions predomi-
nantly in anti-viral and anti-proliferative signaling (Figure 2A;
Ivashkiv and Donlin, 2014). In four EOC cell lines, key upstream
genes in the type I Interferon pathway (IFNb1, IRF7, and
STAT1) were generally upregulated at the fourth day following
the end of Aza treatment (‘‘day 7’’) and further increased by
day 10 (Figures 1C, 1D, S1A, and S1B). Importantly, cytosolic
sensors for DNA (MB21D1/CGAS and TMEM173/STING) and
RNA (DDX41, DDX58/RIG-I, and IFIH1/MDA5) were also variably
upregulated (Figures 1A, 1C, 1D, S1A, and S1B). In A2780 and
TykNu, but not Hey or Kuramochi, cell lines, variable increases
occurred in type III interferon signaling genes, also involved in
response to viruses (Ding and Robek, 2014). These included
IFNL1 (IL28A) and IFNL3 (IL29) ligands (Figure S1C) and espe-
cially the IFN III receptor IFNLR1 (Figure S1C), known to bemeth-
ylated and activated by epigenetic therapy (Ding et al., 2014).
Key viral RNA sensing proteins include TLR3 on the endoso-
mal membrane and MDA5, PKR, and RIG-I in the cytoplasm
(Figure 2A). These induce IRF3, IRF7, and NF-kB to translocate
to the nucleus and activate transcription of IFNb1 (Ivashkiv and
Donlin, 2014). IRF7 is frequently promoter DNA hypermethy-
lated in cancer and the associated low basal expression can
be reversed by Aza in squamous NSCLC (Wrangle et al.,
2013). Among 23 EOC lines examined, IRF7 was hypermethy-
lated in only one, A2780 (Li et al., 2014) (Figure S3A), poten-
tially not a classic high-grade EOC (Anglesio et al., 2013;Cell 162, 974–986, August 27, 2015 ª2015 Elsevier Inc. 975
Figure 2. DNMTis Upregulate Immune
Signaling through Secreted Interferon
(A) Schematic of interferon pathway. Protein
symbols outlined in text.
(B) Treatment of recipient A2780 or TykNu cells
with media from cells treated with Mock or
Aza, +/ addition of anti-IFNb. y axis, qRT-PCR
fold Aza/Mock of ISGs. *p % 0.05 and p^ % 0.05,
respectively, for Mock or Aza media with versus
without anti-IFNb versus Mock or Aza media plus
anti-IFN b.
(C) ELISA of IFNb in media from TykNu cells at day
10 from studies in (B). y axis, pg/mL IFNb.
(D) Treatment of EOC cells with Aza as in Figures
1C and 1D, but in the presence of 2 mM Ruxolitinib
(Rux). y axis, qRT-PCR fold changes for ISGs. *p%
0.05 for fold Aza over Mock and p^% 0.05, Mock or
Aza versusMock +Rux or Aza +Rux. Data, mean ±
SEM of three (B and D) or four (C) biological
replicates.
See also Figure S2.Domcke et al., 2013). Aza induced partial IRF7 demethyla-
tion and increased expression in this cell line at days 7 and
10 while carboplatin did not (Figures 1B, 1C, and S3A), and
IRF7 knockdown significantly reduced the Aza interferon
response (Figures S3B and S3C). Such IRF7 induction did
not occur in two EOC lines or the HCT116 colon cancer cell
line where the gene is not hypermethylated (Figures 1D, S1A,
S1B, and S3A).
When IRF7 is not silenced, other mechanisms must then be
operative for Aza to trigger viral defense signaling. Secreted
IFNb is critical to this signaling and, through interaction with
surface receptors IFNAR1/2, activates JAK/STAT signaling,
transcription of ISGs, and resultant translation inhibition and
apoptosis (Platanias, 2005; Ivashkiv and Donlin, 2014) (Fig-
ure 2A). Indeed, media transferred to untreated cells from Aza-
treated cells 7 days after drug withdrawal caused an interferon
response with increased expression of ISGs IFI27, IFI44, and
IFI44L (Figure 2B). Moreover, Aza treatment induced secreted
IFNb in media (Figures 2C and S2A) and an IFNb blocking anti-
body significantly blocked the Aza-induced ISGmedia response
(Figure 2B). Like type I IFN signaling, type III IFN signaling can be
activated by viral infection (Robek et al., 2005; Ding and Robek,
2014). However, even though we observed upregulation of type
III ligand transcripts IFNL1 (IL28A) and IFNL3 (IL29) (Figure S1C),
secreted type III interferon proteins were undetectable by ELISA
(Figure S2B).
Aza appears to activate type I, IFNb-mediated signaling
through JAK/STAT, as the JAK/STAT inhibitor ruxolitinib strongly
reduced ISG responses (Figures 2D and S2C). Further, antibody
blocking of IFNAR2, the IFNb receptor, abrogated Aza induction
of IFI27, IFI44L, and IFI6 transcription (Figures 3A and S2D),
as did inhibition of IFNb itself (Figures 3B and S2E). In contrast,
blocking the type III interferon, IL10RB receptor, gave only
a modest block of IFI27 increase (Figure S2F). IFNb binding976 Cell 162, 974–986, August 27, 2015 ª2015 Elsevier Inc.to IFNAR2 also may contribute to
late, Aza-induced apoptosis that peaks
at 4–7 days after Aza withdrawal, sinceanti-IFNAR2 led to a lower ratio of cleaved/total PARP (Figures
3A, 3C, and S2D and S2G).
DNMTis Trigger Viral Defense through Induction
of dsRNA
Aza-induced viral defense genes and IFNb1 are not generally
DNA methylated at promoter regions (Li et al., 2014), thus Aza
may activate the pathway upstream of these genes. We consid-
ered increases in dsRNA, viral single-strandedRNA (ssRNA), and
unmethylatedCpGDNA thatmight trigger cytosolic sensors (Sun
et al., 2013). Indeed, 3 days after ending Aza treatment of A2780
and TykNu ovarian cancer cells and subsequent transfection into
HT29 colon cancer cells, known to have a robust interferon
response (Chiappinelli et al., 2012), cytoplasmic total RNA
(without rRNA) and PolyA+ RNA, but not PolyA RNA or DNA,
increased IFNb1 transcripts (Figure 3D) and downstream ISGs
(Figures 3E andS3D). Further, RNaseIII treatment of the cytosolic
nucleic acids, which specifically digests dsRNA, eliminated the
IFNb1 upregulation (Figure 4A), but this was not seen with
RNaseH treatment that digests DNA-RNA hybrids (Figure S4A).
If dsRNA is required for the above Aza effects, then the key
cytosolic sensors, TLR3, MDA5 (IFIH1), and RIG-I (DDX58), the
latter two signaling through the mitochondrial protein, MAVS,
should be involved in subsequent IFNb1 induction (Figure 2A).
Aza increased transcript (Figure 1A) and protein levels for these
(Figure 4B). However, RIG-I, which requires a 50 triphosphate
group on RNA for activation, is likely not a key player since alka-
line phosphatase treatment of cytosolic nucleic acid fractions
did not abolish IFNb1 upregulation (Figure S4D). In contrast,
knockdown of TLR3 and MAVS in A2780 cells (Figure 2A)
decreased Aza upregulation of interferon genes IFNB1, IFI44,
IFI44L, and IFI27 by 2-fold as did MAVS knockdown (Figures
4C, 4D, and S4B). In TykNu, knockdown of TLR3 and MAVS
significantly blunted Aza induction of these gene responses
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Figure 3. Aza Induces Immune Signaling through dsRNA Activation of Secreted Interferon
(A and B) Blocking (A) IFNAR2 (aIFNAR2) or (B) IFNb in TykNu cells treated versus non-treated with Aza as in Figures 1C and 1D; parentheses, U/ml of antibody.
y axis, qRT-PCR for ISGs. *p% 0.05 for (A), Mock or Aza anti-IFNAR2 versus +anti-IFNAR2, (B) Mock or Aza with no anti-IFNb versus with anti-IFNb.
(C) Immunoblotting for cleaved PARP with b-actin loading control. Fold change shown for cleaved/total PARP ratio, normalized to b-actin for each dose of anti-
IFNAR2 (triangles, 0–1.25 U/ml). Aza compared toMock = 1. The A2780 and TykNu cell lysates were run on two separate gels to performwestern blots. The space
in between the PARP and B-Actin proteins was cropped out to conserve space.
(D and E) Indicated nucleic acids from the cytoplasm of A2780- or TykNu-treated cells with no drug (Mock) or 500 nMAza (Aza) for 3 days and rested without drug
for 4 days before transfection into recipient HT29 cells. y axis, fold change, Aza/Mock, for IFNb1 transcript (D) or ISG transcripts (E) induced in HT29s. No Tx, no
transfection; Cyto DNA, cytoplasmic DNA; Cyto RNA, cytoplasmic RNA excluding rRNA. *p% 0.05 for (D) fold change Aza versusMock, (E) Aza/Mock. Data in (A),
(B), (D), and (E) are mean ± SEM of three biological replicates.
See also Figure S3.(Figure S4C). Importantly, knock down of STING, the cytosolic
DNA sensor (Mankan et al., 2014) did not blunt Aza-induced
interferon signaling (Figures 4C and 4D). A previous report had
implicated STING in viral cytosolic sensing in B cells, but this
was dependent upon viral reverse transcriptase activity, likely
to be low in our cells (Mankan et al., 2014). We thus conclude
thatMAVS and TLR3 are centrally involved in Aza triggering cyto-
solic sensors to induce an interferon response.
Aza-Induced Human Endogenous Retrovirus
Transcripts Can Activate Viral Defense
Responses in EOC
The above data suggests Aza might activate endogenous retro-
viral sequences (ERVs) that constitute more than 8% of the
human genome, can activate cytosolic RNA sensors, and are
silenced in normal somatic cells by promoter DNA methylation
(Bannert and Kurth, 2004; Tristem, 2000; Hurst and Magiorkinis,2014;Mankan et al., 2014). Some cancers lose ERVDNAmethyl-
ation and aberrantly overexpress ERVs (Larsen et al., 2009;
Rycaj et al., 2015; Strick et al., 2007; Strissel et al., 2012;
Wang-Johanning et al., 2001, 2007) while others maintain
silencing. Aza can induce specific ERV transcripts in melanoma,
choriocarcinoma, and endometrial cancer cells (Laska et al.,
2013; Ruebner et al., 2013; Stengel et al., 2010; Strissel et al.,
2012). Indeed, in initial testing, the ERVK subfamily (Wang-
Johanning et al., 2003) transcripts increased 2.5-fold in the
A2780 cell line upon Aza treatment (data not shown). Upregula-
tion of individual ERVs (22 full-length env, 6 partial coding env,
1 full-length gag, and 2 partial coding pols) (Tables S1 and S2),
in PCR assays for non-repeat sequences, occured especially
at day 7 (coinciding with ISG expression) in three EOC lines
following Aza and Dac treatment (Figures 5A, 5B, and S5A–
S5C). These included several known ERV env genes like
Syncytin-1, ERV-3, env-K, and env-H (Blond et al., 1999; Lo¨werCell 162, 974–986, August 27, 2015 ª2015 Elsevier Inc. 977
Figure 4. Aza Activates dsRNA Sensors to Induce Interferon Signaling
(A) Effects on IFNb1 transcripts, at 24 hr, in HT29 recipient cells transfected with nucleic acid fractions, treated with RNaseIII, from A2780 as in Figures 3D and 3E.
IFNb1 transcripts were measured at 24 hr. y axis = IFNB1 fold change, *p% 0.05 for fold change over untreated; p^% 0.05 for Mock or Aza + versus  RNaseIII.
(B)Western blots for MDA5, RIG-I, and TLR3 in A2780 cells at four (day 7) and seven (day 10) days after Mock versus 500 nMAza (Aza) for 3 days. The same A2780
lysate gel was blotted for MDA5 and b-actin, then stripped and reprobed for RIG-I and TLR3. The space between theMDA5, RIG-I, and TLR3 and b-actin proteins
was cropped out to conserve space.
(C) Knockdown upon lentiviral infection, with puromycin selection, of A2780 and TykNu with shGFP, shTLR3, and shSTING hairpins. Immunoblotting with anti-
TLR3, anti-STING, and anti-b-actin. Densitometry fold change, normalized to mock or shGFP, shown at the bottom of the gels. The shTLR3 and shSTING cell
lysates were run on two separate gels to perform western blots. The space in between the TLR3 and b-actin proteins was cropped out to conserve space. The
STING western blot was stripped and reprobed with b-actin as a loading control.
(D) qRT-PCR for ISGs from (B) and (C). *p% 0.05 Aza over Mock; p^% 0.05 shGFP versus each shRNA sensor with mean fold change ± SEM of three biological
replicates.
See also Figure S4.et al., 1993; Mi et al., 2000; Rote et al., 2004) and at especially
high levels, env-Fc2, a less well-characterized gene (Be´nit
et al., 2003). Finally, in DKO as well as Aza-treated A2780 and
TykNu cells, loss of env-Fc2 promoter methylation correlated
with increased Fc2 expression (Figures 5B, 6A–6C, and S6A)
but not in Hey cells (Figure S6A).
Further linking ERVs with a dsRNA-triggered IFN response,
bidirectional transcription producing sense and anti-sense tran-
scripts occurred for Syncytin-1 and five env-Fc2 gene loci, but
not b-actin, in three EOC lines and HCT 116 and DKO cells (Fig-
ure 5C; Table S2), analyzed by the TAG-aided sense/antisense
transcript detection (TASA-TD) technique (Henke et al., 2015).
Such sense and antisense transcripts can form dsRNA (Faghihi
et al., 2008; Su et al., 2012). Interestingly for TykNu, there was
a 6.69-fold increase of env-Fc2 antisense transcript levels
compared to the sense transcript (Figure 5C) but substantially978 Cell 162, 974–986, August 27, 2015 ª2015 Elsevier Inc.lower antisense transcripts were seen in both HCT116 and
DKO cells (Figures 5C and 6A). Disrupting DNMTs seems inte-
gral to the above ERV upregulation since increases of env-Fc2
and erv9-1 occurred in DKO versus wild-type HCT116 cells
(Figure 6A).
ERV transcripts seem directly involved in the Aza responses
that, first, although drug-induced upregulation of ERV transcripts
began early after Aza, both ERVs and viral defense gene in-
creases generally peaked by day 7 (Figures S6D and S6J). Sec-
ond, ERV env proteins such as Syn1 and ERV-3 were not
increased after Aza treatment, supporting a dominant role for
viral defense signaling via RNA transcripts (Figures 6D, S6B,
and S6C). Third, overexpression of ERV-3, EnvW2, and Syncy-
tin-1 in TykNu (Figures 6E and 6J), A2780 (Figure S6D), and
Hey cells (Figures S6E and S6J), as compared to control genes,
increased the same interferon genes induced by Aza (IFNb1,
AB
C
Figure 5. Aza Upregulates Sense and Antisense ERV Transcripts
RNA was isolated from cells at last (day 3), one (day 4), three (day 7), and seven (day 10) days after Mock or 500 nM Aza (Aza) for 3 days.
(A) Total number of molecules for all ERV genes (y axis = ERV molecules/ng RNA). Error bars, SEM for four independent experiments; numbers above bars,
significant data for indicated days; gray, Mock; black, Aza.
(B) qRT-PCR of ERV genes in A2780 cells for four independent experiments. y axis, fold increases for Aza/Mock ± SEM and normalized to Mock = 1. White bars,
non-significant; colored bars, significant ERV gene induction (p < 0.05).
(C) TASA-TD PCR amplified sense and antisense transcripts of the env-Fc2 (731 bp) and Syncytin-1 (202 bp) genes from first strand cDNA. Aza-treated A2780,
Hey, and TykNu, and HCT116 and DKO cells are indicated. Ratios of sense (s) and antisense (as) determined by ImageJ. PCR primers, gene-specific (GS); TAG.
b-actin sense 399 bp amplification product = negative control for as transcripts (Chen et al., 2004). The products from TASA-TD PCR were run on the same gel,
then cropped and presented.
See also Figure S5.IFI27, and IFI44L). The increases often exceeded that for the
drug likely because total ERV RNA molecules were higher
in the overexpression experiments (Figures S6F–S6I). Finally,
although siRNA knockdown of individual ERVs (Syncytin-1,
ERV-3) during Aza treatment produced more complex results,
targeting two ERVs significantly blunted the Aza-induced gene
expression of IFI27, IFI44L, and IFI6 in TykNu cells, but not
A2780 or Hey cells (Figure S7A).
Importantly, a driving role for ERV transcripts in triggering
Aza-induced viral defense gene responses is evidenced by a
high correlation of basal levels of both in 19 primary EOC. Total
molecules of 22 ERV env genes queried were increased (p <
0.05) in tumor versus normal (n = 9) and divided tumors into
lower (n = 9) and higher ERV (n = 10) expression groups as
compared to normal controls. High ERV tumors had significantly
higher viral defense response gene expression (p = 0.000141)
(Figure 7A).Viral Defense Gene Levels Divide Human Tumors into
High and Low Expression Groups that Track with
Responses to Immune Checkpoint Therapy
Human cancers can evolve immune evasion to become less
responsive to immune modulation (Drake et al., 2006; Schreiber
et al., 2011). In this regard, basal transcript levels for the Aza-
induced viral defense genesgroupedprimaryEOC,breast, colon,
and lung cancers, andmelanoma fromTheCancerGenomeAtlas
(TCGA) studies into high and low groups (Figures 7B and S7C–
S7F). For EOC, this basal expression divided tumors into high,
medium, and low expression groups and the former two encom-
pass virtually all of the TCGA (Verhaak et al., 2013) immune reac-
tive (IMR) good prognosis tumors. The Low group encompasses
the PRO (high proliferative), poor prognosis subtype (p < 0.001 to
0.0001) (Figures 7B and S7B). Interestingly, virtually all of the
right-sided colon cancers with a high DNA hypermethylation fre-
quency phenotype (p < 0.002), termed CIMP, which have a highCell 162, 974–986, August 27, 2015 ª2015 Elsevier Inc. 979
Figure 6. Aza Upregulates ERV Transcripts, but Not Proteins, through DNA Demethylation
(A) env-Fc2 and erv-9-1 ERV gene total number of molecules, assayed by qRT-PCR, for DKO (DNMT1/, DNMT3B/) and parental HCT116 cells. y axis, mean ±
SEM for n = 6 biological replicates.
(B) DNAmethylation changes in ERVs in A2780 cells treatedwithMock or 500 nMAza for 3 days at post-treatment day 4 (day 7) or 7 (day 10). Bisulfite-treated DNA
was amplified and digested with the AciI enzyme producing 155 and 44 bp fragments of methylated DNA while unmethylated DNA does not digest (199 bp
fragment). U, unmethylated band; M, methylated band.
(C) DNA from (B) was subjected to methylation-specific PCR for ERV-Fc2 family members on chromosomes 7 and 11. U, unmethylated; M, methylated;
IVD, in vitro methylated DNA. The products from the sameMSP reaction were run on two different gels and presented together. Vertical line indicates distinction
between gels on the left and right.
(D) Syncytin-1 and ERV-3 protein levels in EOC cells treated as in (B). Fold change for densitometry by ImageJ for Aza versus Mock cells normalized to b-actin
protein levels. The same gel blotted for Syncytin-1 and b-actin, then stripped and reprobed for ERV3. The space between the Syncytin-1 and ERV3 and the b-actin
proteins was cropped out to conserve space.
(E) Transfection of full-length env genes fromEnvW2, ERV-3, or Syncytin-1 or EGFP and ER controls in TykNu cells. qRT-PCRwas performed for ISGs 7 days after
transfection. Dotted black line indicates 1. Y axis, mean ± SEM fold change of three biological replicates for overexpression/Mock. *p% 0.05.
See also Figure S6.burden of DNA mutations and respond robustly to immune
checkpoint therapy (Le et al., 2015),were in theHigh and Interme-
diate groups (Figure S7C). High mutation burden has recently
been defined as a key correlate to response to immune check-
point therapy (Rizvi et al., 2015; Snyder et al., 2014). Similar sharp
high versus low clustering is seen for subgroups of breast and
lung cancers and melanoma (Guan et al., 2015) (Figures S7D–
S7F), the last being very responsive to immune checkpoint ther-
apy (Topalian et al., 2015; Hodi et al., 2010; Weber et al., 2015).
Could the levels of viral defense pathway signaling corre-
late with improved responses to immune checkpoint therapy?
Indeed, for RNA-seq transcriptomes of melanoma patients
treated with anti-CTLA-4, high levels of the viral defense
signature expression in tumor samples correlated with long980 Cell 162, 974–986, August 27, 2015 ª2015 Elsevier Inc.term benefit (disease control [stable disease or better] >6months
as measured radiographically) in patients treated with anti-
CTLA-4 therapy (Snyder et al., 2014) (Figures 7C and 7D; Tables
S5 and S6). Importantly, high viral defense signature again corre-
lated with high mutational burden (Figure 7C).
Aza Treatment Potentiates ImmuneCheckpoint Therapy
in a Mouse Model of Melanoma
In the B16-F10 mouse melanoma model, multiple combinations
of low dose Aza directly enhanced tumor responses to anti-
CTLA4 immune checkpoint therapy (Figures 7E, 7F, and S7G).
Further, B16 cells treated in vitro with Aza, then injected
intomice and treated with anti-CTLA-4, were cleared completely
(data not shown). Thus DNMTis can potentiate the anti-tumor
effects of immune checkpoint inhibitors.
Figure 7. Aza-Upregulated Viral Defense Genes Are Significantly Correlated with ERVs in Primary Tumors and Correlate with Sensitivity to
Immune Therapy
(A) Heatmap comparing basal levels of viral defense genes and ERVs in primary EOC. The cut-off for lower or higher ERVs was the mean control tissue value of
237.57 ± 83.05 molecules/ng RNA. Mean ISGs of the high ERV ovarian tumor (T) cohort (n = 10) is 12.65-fold higher than the mean of ISGs of the low ERV cohort
(n = 9). The (*) denotes that eight of ten high ERV tumors had significantly higher ISG expression compared to the low ERV tumors. ISG expression is organized
according to low and high ERV expression cohorts in arbitrary units; color code from blue to red shows increasing ISG expression. For clusters (k = 6), differences
are significant between the high ERV expression (2.5 ± 0.37) and the low ERV expression cohort (5.33 ± 0.28).
(B) Interferon-stimulated viral defense genes upregulated at least 2-fold by Aza in EOC cell lines (right y axis) were used to cluster EOC tumors for RNA-seq data
(blue, low; red, high) from The Cancer Genome Atlas (TCGA). EOC TCGA subtypes are shown: DIF (differentiated), IMR (immune reactive), MES (mesenchymal),
and PRO (proliferative).
(C and D) Viral defense gene signature is upregulated in tumors from anti-CTLA-4-treated metastatic melanoma patients who derived durable clinical benefit
(complete response, partial response, or progression free-survival >6 months as previously described) (Snyder et al., 2014) compared to those without benefit.
Tumors collected pre-CTLA-4 treatment and shortly post-treatment are shown.
(D) y axis = RFPKM mean of viral defense genes in all melanoma patients.
(E and F) Tumor responses ofmice injectedwith B16-F10 cells and treatedwith either PBS, anti-CTLA-4, Aza, or both anti-CTLA-4 and Aza. Data represent results
from one of two independent experiments with identical results, each with n = 10 per arm. Y axis = mean tumor surface, error bars ± SEM.
See also Figure S7 and Tables S5 and S6.DISCUSSION
Our present data now provide functional context for our earlier
reports that DNMTis induce a complex set of immune pathway
responses in tumor cells (Li et al., 2014; Wrangle et al., 2013).
DNMTis trigger cytoplasmic dsRNA sensing, central to cellular
viral defense responses, and activate interferon in EOC and
colon cancer cells by disrupting DNMTs. This activation couldinduce tumor attraction of lymphocytes (Ivashkiv and Donlin,
2014). There are some important implications for one of the
most exciting new developments in cancer treatment, immune
checkpoint therapy (Brahmer et al., 2010, 2012; Berger et al.,
2008; Leach et al., 1996; Topalian et al., 2015; Hodi et al.,
2010; Weber et al., 2015) and for underlying mechanisms
inherent to both tumor and host cells for reversal of immune
tolerance in tumor infiltrating T-lymphocytes (Pardoll, 2012).Cell 162, 974–986, August 27, 2015 ª2015 Elsevier Inc. 981
Indeed, basal levels of our viral defense gene transcripts divide
EOC, and other major cancer types in TCGA, into low and high
expression subgroups. Perhaps most intriguingly, such high
basal expression in tumors tracks with favorable patient re-
sponses in a trial of immune checkpoint therapy for advanced
melanoma, and strong Aza sensitization to immune checkpoint
therapy is seen in a pre-clinical mouse melanoma model.
A major trigger of the Aza-induced viral defense response ap-
pears to be bidirectional transcription of ERVs that are known to
fold into dsRNA secondary structures. ERVs, representing more
than 8% of the human genome (Bannert and Kurth, 2004; Tris-
tem, 2000), integrated into the genome of mammals between
0.1 and 40 million years ago via exogenous retroviral infections
of germ cells (Egan et al., 2004; Turner et al., 2001). Most ERV
genes are non-functional due to DNA recombination, mutations,
and deletions, but some produce functional proteins including
group-specific antigen (gag), polymerase (pol) with reverse tran-
scriptase (RT), and the envelope (env) surface unit (SU) with a
transmembrane immunosuppressive-like peptide (Mi et al.,
2000; Blaise et al., 2005; de Parseval et al., 2003; Villesen
et al., 2004). The env gene of ERVW-1 (chromosome 7q21.2)
called Syncytin-1 has an essential role in placentogenesis (Blond
et al., 1999; Mi et al., 2000).
Importantly, and key to our findings, a major function of
DNA methylation in humans is silencing of ERVs and other
viral sequences in the human genome; up to 90% of methyl-
ated CpGs are located in 45% of the human genome
harboring repetitive elements like ERVs (Walsh et al., 1998;
Bestor and Tycko, 1996). However, ERV genes are unmethy-
lated and expressed in embryonic stem cells (Santoni et al.,
2012) and especially Syncytin-1 is epigenetically regulated
throughout placentogenesis (Matouskova´ et al., 2006). Some
tumors have ERV demethylation and increased expression
such as the ERV-K (HML-2) 50LTR-UTR in melanoma (Stengel
et al., 2010) and the 50-LTR region of several ERVs in testicular
cancer (Gimenez et al., 2010). A 20% overall mean demethyla-
tion of single CpGs in the ERVW-1 50 LTR regulating Syncytin-1
correlates with increased expression in endometrial cancer
(Strissel et al., 2012). Indeed, ERVs can be targeted as tu-
mor-associated antigens on melanoma cells (Cooper et al.,
2015). In contrast, as in our present data and those of others
(Maksakova et al., 2008), in some cancers, individual ERVs
can maintain full or partial promoter DNA methylation and low
expression and DNMTis can induce ERV demethylation and
viral defense signaling in human embryonic stem cells (Grow
et al., 2015).
In addition to ERVs, other noncoding RNAs could contribute to
the Aza-induced immune response, such as repetitive Alu ele-
ments (Tarallo et al., 2012). UV light can damage small nucleolar
RNA and activate an interferon response via TLR3 (Bernard et al.,
2012) and very high dose (10 mM) Dac can induce an interferon
response, apoptosis, increased ERVs and repetitive satellite
RNAs in p53 null mouse fibroblasts (Leonova et al., 2013). We
suspect, however, that such high Dac doses induce DNA
damage rather than simply epigenetic effects. Half of the ovarian
cancer lines we studied (Li et al., 2014) have wild-type P53 but
we see no differences in Aza interferon response between these
and those with mutant P53.982 Cell 162, 974–986, August 27, 2015 ª2015 Elsevier Inc.The high translational connotations of our findings, including
the small number of patients in clinical trials for NSCLC who
may have been sensitized by epigenetic priming to immune
therapy (Wrangle et al., 2013), remain to be validated in larger
clinical trials. These are ongoing for NSCLC (Brahmer, 2015)
and planned for advanced ovarian cancer. Moreover, ERV-K
env proteins have been shown to increase immunotherapeutic
potential of melanoma, breast, and ovarian cancer patients
(Rycaj et al., 2015; Wang-Johanning et al., 2012; Cooper
et al., 2015). Also, our hypotheses that drugs like Aza might
sensitize patients with multiple cancer types to immune check-
point blockade and other immunotherapies are further strength-
ened by the data in our pre-clinical melanoma model. For
immune checkpoint therapy, in addition to the functional
significance of our data, a potential biomarker strategy is sug-
gested by our findings in a melanoma trial. The high correlation
of viral defense signaling with mutational burden suggests that
genetic changes, increases in ERVs, and viral defense genes
could predict response to immune checkpoint and other immu-
nomodulatory approaches. Finally, our drug approach to upre-
gulate viral defense signaling might be compared to the use of
oncolytic viruses to induce inflammatory immune infiltrates at
tumor sites to sensitize to immunomodulation (Zamarin et al.,
2014).
EXPERIMENTAL PROCEDURES
Detailed materials and methods can be found in the Supplemental Experi-
mental Procedures.
Cell Line Treatments
Cell lines were treated with 500 nM Aza, 100 nM Dac, or 500 nM-3 mM
carboplatin (Sigma) for 72 hr, and DNA and RNA were isolated using stan-
dard methods at 1, 3, or 7 days following removal of drug. Ruxolitinib
(2 mM) (Invivogen tlrl-rux), 0.625–5 U/ml of anti-IFNAR2 antibody (PBL
Interferon Source 21385-1), 0.625–2.5 U/ml of anti-IFNB antibody (PBL Inter-
feron Source 31400-1), or 1.25–5 U/ml of anti-IL10RB antibody (Abcam
ab89884) were added during DNMTi treatment. Preparation of nuclear and
cytoplasmic fractions of cultured cells was performed as described (O’Hagan
et al., 2011). Ribosomal RNA was depleted using the Ribominus kit
(Invitrogen), and PolyA+ and PolyA RNA were isolated using the Oligotex
Direct mRNA Mini Kit (Invitrogen). Nucleic acids were treated with 1 U/mg
of RNase III (Ambion), 10 U/mg of RNaseH (Invitrogen), or 3 U/1 mg calf intes-
tine alkaline phosphatase (New England Biolabs) according to manufac-
turer’s instructions, and 400 ng of each nucleic acid was transfected into
HT29 cells.
DNA Methylation Analysis
DNA was bisulfite converted and subjected to methylation-specific PCR (Her-
man et al., 1996) for IRF7 and ERV-Fc2 and COBRA (Xiong and Laird, 1997) for
the ERV-Fc2 locus on chromosome 11.
Transcript Abundance
Real-time RT-PCR was performed with an Applied Biosystems 7500 Fast
Real-Time PCR machine by the 2DDCT method and TASA-TD strand-specific
PCR by the method of Henke et al. (2015).
Protein Analysis
Western blot analyses employed antibodies against ERV-3 (1:1,000, Everest),
B-actin (1:5,000, Sigma), MDA5 (1:1,000, Cell Signaling 5321), PARP (9542,
1:1,000; Cell Signaling Technology), RIG-I (1:1,000, Cell Signaling 4200),
STING (1:1,000, Abcam ab82960), Syncytin-1 (1:350, Dr. Herve´ Perron, Gen-
euro, Geneva Switzerland), and TLR3 (1:1,000, Cell Signaling 6961). IFNB
ELISA utilized the Verikine-HS Human Interferon Beta Serum ELISA kit (PBL
Interferon Source) and IFNL ELISA the DuoSet ELISA for Human IL-29/
IL28-B (IFNL 1/3) kit (R&D Systems).
Knockdown and Overexpression Experiments
Syncytin-1, ERV-3 and ERV-W2 env, Estrogen receptor alpha (ER), and E-GFP
vectors and siRNAs targeting Syncytin-1, ERV-3, or a scrambled control, were
transfected using the JetPei or Hyperfect transfection reagents, respectively.
TLR3, MAVS, and STING shRNA were performed according to established
methods (Stewart et al., 2003).
RNA-Seq Expression Analysis of Tumors from Anti-CTLA-4-Treated
Patients
Patients were described previously (Snyder et al., 2014) and samples were ob-
tained with written informed consent per approved institutional review board
(IRB) protocols. Expression data were obtained using RNA-seq with all data
deposited at The cBio portal under the study name Metastatic Melanoma
(MSKCC Cell, 2015).
B16-F10 Melanoma Mouse Model
C57BL/6J mice were subcutaneously injected with 1 3 105 B16-F10 tumor
cells. On days 4, 8, 11, 14, and 18, mice were treated intraperitoneally
with 100 mg anti-ctla-4. Mice received two cycles of intraperitoneal injec-
tion of 0.1 to 0.75 mg/kg Aza in PBS for 5 consecutive days followed by
7 days off treatment, starting at day 8 after developing palpable tumors,
with control groups receiving corresponding doses of non-specific isotype
antibody control and PBS intraperitoneally. Tumor surface was measured
with a caliper using the ellipse surface formula (length 3 width 3 p)/400.
All mouse procedures were performed in accordance with the institutional
protocol guidelines from the Memorial Sloan Kettering Cancer Center (New
York, NY).
Statistical Analysis
Mean ± SEM qRT-PCR results were considered statistically significant with
p values % 0.05 by Mann-Whitney U test or Student’s t tests and two-tailed
p values are reported. Tumor growth was assessed by two-way ANOVA
between each of the mouse treatment groups with p values adjusted by the
Dunnett multiple comparison test (df = 512).
Normalized, level 3 Agilent expression data were obtained from The Cancer
Genome Atlas data portal (https://tcga-data.nci.nih.gov/tcga/) and analyzed
by R statistical software (http://www.r-project.org) with existing packages
and customized routines. Consensus hierarchical clustering was performed
with the ConsensusClusterPlus R-package (Wilkerson and Hayes, 2010)
and data analyzed by the Fisher exact p value test for association between
clusters.
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